Literature DB >> 12432832

Neurofibromatosis 1.

Timothy M Lynch1, David H Gutmann.   

Abstract

Neurofibromatosis 1 is one of the most common genetic conditions affecting the nervous system. Individuals with NF1 are predisposed to the development of peripheral nerve sheath tumors (neurofibromas and MPNSTs), astrocytomas (optic pathway gliomas), learning disabilities, seizures, strokes, macrocephaly, and vascular abnormalities. The NF1 tumor suppressor gene encodes a large protein (neurofibromin) that functions primarily as a RAS negative regulator, suggesting that targeted therapy for NF1 might derive from inhibition of the RAS signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432832     DOI: 10.1016/s0733-8619(01)00019-6

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  31 in total

Review 1.  Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

Authors:  C Shilyansky; Y S Lee; A J Silva
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

2.  Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation.

Authors:  Seung Tae Baek; Michelle D Tallquist
Journal:  Development       Date:  2012-04-25       Impact factor: 6.868

3.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

4.  Reproducibility of circumpapillary retinal nerve fiber layer measurements using handheld optical coherence tomography in sedated children.

Authors:  Robert A Avery; Avital Cnaan; Joel S Schuman; Chieh-Li Chen; Natalie C Glaug; Roger J Packer; Graham E Quinn; Hiroshi Ishikawa
Journal:  Am J Ophthalmol       Date:  2014-06-28       Impact factor: 5.258

5.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

6.  Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.

Authors:  Robert A Avery; Eugene I Hwang; Hiroshi Ishikawa; Maria T Acosta; Kelly A Hutcheson; Domiciano Santos; Dina J Zand; Lindsay B Kilburn; Kenneth N Rosenbaum; Brian R Rood; Joel S Schuman; Roger J Packer
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

7.  Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.

Authors:  Robert A Avery; Eva Dombi; Kelly A Hutcheson; Maria T Acosta; Andrea M Baldwin; William P Madigan; Andrea Gillespie; Edmond J Fitzgibbon; Roger J Packer; Brigitte C Widemann
Journal:  Am J Ophthalmol       Date:  2013-02-26       Impact factor: 5.258

8.  Neurofibromin regulation of ERK signaling modulates GABA release and learning.

Authors:  Yijun Cui; Rui M Costa; Geoffrey G Murphy; Ype Elgersma; Yuan Zhu; David H Gutmann; Luis F Parada; Istvan Mody; Alcino J Silva
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

9.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

10.  Neurofibromatosis type 1 and high-grade tumors of the central nervous system.

Authors:  Amy Rosenfeld; Robert Listernick; Joel Charrow; Stewart Goldman
Journal:  Childs Nerv Syst       Date:  2009-11-25       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.